ライフサイエンスコーパス: disappointing

1 ing genes for multifactorial stroke has been disappointing.

2 whose cause is unclear and treatment remains disappointing.

3 compounds in human clinical trials has been disappointing.

4 to acetylcholinesterase inhibitors is often disappointing.

5 presenting at an advanced stage is therefore disappointing.

6 mpts to solve this problem have been largely disappointing.

7 alone in this patient group has proven to be disappointing.

8 ere developed, but clinical trials have been disappointing.

9 and the replication among studies is rather disappointing.

10 unmodified antisense RNAs has generally been disappointing.

11 d in patients with myeloma, and results were disappointing.

12 the outcome of cell transplantation remains disappointing.

13 r peripheral nerve repair in humans is often disappointing.

14 istors' power amplification ability has been disappointing.

15 y-dwelling adults, which, to date, have been disappointing.

16 hat adherence to health education advice was disappointing.

17 nism, and VEGF delivery to patients has been disappointing.

18 s with known proangiogenic factors have been disappointing.

19 sis to provide improved resolution have been disappointing.

20 ion to the diagnostic armamentarium has been disappointing.

21 us clinical trials with this agent have been disappointing.

22 t of fulminant colitis in children have been disappointing.

23 V squamous cell head and neck cancer remains disappointing.

24 urodegenerative diseases has been meager and disappointing.

25 overall survival with this approach has been disappointing.

26 in diseases where conventional DLI has been disappointing.

27 e clinical trials (oral administration) were disappointing.

28 tients with congenital corneal opacities are disappointing.

29 ment of bacterial vaginosis in pregnancy are disappointing.

30 -D monoclonal antibodies have been, at best, disappointing.

31 pancreatography pancreatitis (ERCP) has been disappointing.

32 odies and nuclear medicine imaging have been disappointing.

33 ical effectiveness of immunotherapy has been disappointing.

34 ine therapy in the adjuvant setting has been disappointing.

35 ces and antiarrhythmic drug therapy has been disappointing.

36 ablation therapy for many patients has been disappointing.

37 onists in congestive heart failure have been disappointing.

38 IDs) in the treatment of AD have so far been disappointing.

39 t, is common and the 5-year survival rate is disappointing.

40 However, results have been disappointing.

41 nventional immunosuppressive agents has been disappointing.

42 ividual genetic abnormalities have also been disappointing.

43 patients with Parkinson's disease have been disappointing.

44 cells for therapeutic applications have been disappointing.

45 infarction, and hemorrhagic shock-have been disappointing.

46 but the results for larger tumors have been disappointing.

47 The results of these trials have been disappointing.

48 e results of islet transplantation have been disappointing.

49 complex traits has been difficult and often disappointing.

50 SWL) for lower calyceal stones are generally disappointing.

51 ent of autoimmune disease in humans has been disappointing.

52 g in-stent restenosis have been consistently disappointing.

53 rts, but our results have in some cases been disappointing.

54 es, the overall impact on pathology has been disappointing.

55 s to identify the underlying genes have been disappointing.

56 eous sarcoidosis is easy, but the therapy is disappointing.

57 antioxidants have, however, been clinically disappointing.

58 ts of therapy with D-penicillamine have been disappointing.

59 treat autoimmune disease have been somewhat disappointing.

60 roblem for which medical management has been disappointing.

61 ation of this science to technology has been disappointing.

62 y the routine use of growth factors has been disappointing.

63 prognosis for advanced stage disease remains disappointing.

64 IFN protein therapy of solid tumors has been disappointing.

65 ure rates for head and neck cancer have been disappointing.

66 noclonal antilymphocyte antibodies have been disappointing.

67 nts for cancer on mortality has been largely disappointing.

68 these phenylalanine-based peptides is often disappointing.

69 lts of treating these small tumors have been disappointing.

70 arinone, pimobendan, and ibopamine have been disappointing.

71 otent vasodilator prostaglandin E1 have been disappointing.

72 fusion to clinical practice has to date been disappointing.

73 ceutical, but subsequent investigations were disappointing.

74 Pharmacological treatments were disappointing.

75 rates to therapeutic clinical trials remain disappointing.

76 sults with anti-angiogenic therapy have been disappointing.

77 , gains from second-line therapies have been disappointing.

78 sults of clinical trials have generally been disappointing.

79 cardioversion in restoring sinus rhythm was disappointing.

80 romising results, trials in humans have been disappointing.

81 cancer antigen 125 as an antigen, have been disappointing.

82 inues, the clinical return has thus far been disappointing.

83 New treatments of refractory GERD have been disappointing.

84 om a generation ago, is generally still very disappointing.

85 how brain processes cause consciousness are disappointing.

86 ancers to immune therapies has thus far been disappointing.

87 ght to drive tumor growth, results have been disappointing.

88 factor control in clinical practice has been disappointing.

89 anoma, their use in ocular variants has been disappointing.

90 for acute myeloid leukemia (AML) has proved disappointing.

91 cines in phase IIa/b clinical trials remains disappointing.

92 rods and found that this approach is rather disappointing.

93 Overall 5-year patient survival was a disappointing 35%.

94 s of sleep-disordered breathing have shown a disappointing ability to predict important consequences

95 ibition using sulfonylurea agents has proved disappointing, although agents acting on its pore appear

96 vitamin E supplements and cataract have been disappointing and are not yet available for selenium.

97 s to identify genetic variants have produced disappointing and contradictory results.

98 th oncogenic RAS signaling have been largely disappointing and have not resulted in meaningful clinic

99 py to inhaled corticosteroids, they are also disappointing and less effective than long-acting beta(2

100 The treatment of SLE remains disappointing and no controlled trials for neurological

101 Current treatments are disappointing and often have little beneficial effect.

102 immunosuppressive drugs has been relatively disappointing and there have been few efforts in definin

103 , clinical activity in solid tumors has been disappointing and toxicity has been a serious concern.

104 for persistent atrial fibrillation (AF) are disappointing and usually do not exceed 60%.

105 models are still widely used, but have been disappointing, and development of genetic models has giv

106 ept in the treatment of sarcoidosis has been disappointing, and may actually cause the disease.

107 ed epithelial ovarian carcinoma (EOC) remain disappointing, and the development of more effective pri

108 ted therapy for solid tumors has so far been disappointing, and the reasons for this poor response in

109 greater clinical impact than have the so far disappointing antisense endeavors.

110 tely, results from clinical trials have been disappointing as off-target effects and toxicities have

111 sis," Sriram and Steiner(1) wrote, "The most disappointing aspect of EAE [experimental allergic encep

112 ials of ARIs on diabetic neuropathy appeared disappointing because of either 1) their inadequate desi

113 of HCV treatment in this population has been disappointing because of low rates of treatment initiati

114 iences with EGFR kinase inhibitors have been disappointing, because resistance is common and tumors e

115 idual hormone/mediator have yielded somewhat disappointing body weight changes, often leading to the

116 candidate vaccine and microbicide have been disappointing, both for want of efficacy and concerns ab

117 an, interferon gamma, and relaxin) have been disappointing but new strategies against fibrosis based

118 ography has proved inconsistent and somewhat disappointing but single photon emission computed tomogr

119 icide candidates in efficacy trials has been disappointing, but next-generation concepts now in or ap

120 ediator antagonists tested in COPD have been disappointing, but of CXCR2 antagonists that block pulmo

121 Considering the disappointing clinical activity of HSP90 inhibitors in o

122 targets and lead to improvement of the still disappointing clinical outcome of these patients.

123 fusion of red blood cells has been linked to disappointing clinical outcomes in the critically ill, b

124 ir stem cell function, and could explain the disappointing clinical results in many current gene tran

125 eptor (EGFR)-targeted therapies have yielded disappointing clinical results in treatment of this canc

126 E) to prevent lung cancer have produced only disappointing clinical results to date.

127 vered, perhaps an explanation for the so-far disappointing clinical translation to the prevention and

128 ouraging experimental work has led so far to disappointing clinical trials and the identification of

129 ta in humans with one agent (infliximab) but disappointing controlled data from another (etanercept).

130 c strategies that will improve the currently disappointing cure rate (approximately 25-40%) of this g

131 myocardial infarction, have provided largely disappointing data.

132 hrenia have yielded both promising leads and disappointing dead ends, indicating the multifactored an

133 geted inhibition of EGFR has been clinically disappointing, demonstrating an innate ability for GBM t

134 autoimmune diseases have often been notably disappointing despite many claims for linkages.

135 w antibacterial agents has been particularly disappointing, despite a plethora of potential targets,

136 poptotic receptor agonists (PARAs) have been disappointing, despite compelling preclinical efficacy w

137 ng antioxidant supplements have been equally disappointing, despite the clear benefits of a healthy d

138 ing TNF-alpha for cancer treatment have been disappointing due in part to its severe side effects, an

139 alysts, their enzymatic performance has been disappointing due to low reaction rates.

140 nisms for exercise hyperaemia are especially disappointing due to the essentially concurrent discover

141 tibodies for use as cancer vaccines has been disappointing due to the weak immunogenicity of immunogl

142 ng program implementation, results have been disappointing, e.g., only 7% of candidates passing the p

143 ith two devices have been stopped because of disappointing early results.

144 n clinical trials, MEK inhibitors have shown disappointing efficacy in mutant NRAS patients, the reas

145 s for solid-organ transplantation have shown disappointing efficacy in the prevention of chronic allo

146 Disappointing efficacy of 11betaHSD1 inhibitors in phase

147 The disappointing efficacy of blood-stage malaria vaccines m

148 ain a better understanding of the clinically disappointing EGFR-targeted therapies for GBM, we invest

149 of the tests with glans swab specimens were disappointing except for those from patients with sympto

150 ecific antisense have resulted in an overall disappointing experience.

151 nagement strategies, highlighting the rather disappointing experiences with mechanical and systemic d

152 sharp contrast to the fit-to-cohort effect, disappointing findings to date, and limited reproducibil

153 ting vasculature may, in part, explain these disappointing findings.

154 rvival and overall survival, however, remain disappointing for children with metastatic RMS at diagno

155 However, blockade of EGFR is therapeutically disappointing for gliomas with PTEN deletion.

156 neic stem cell transplantation (SCT) but are disappointing for other diseases.

157 Nothing is more disappointing for patients than when a promising new tre

158 ise as a thermal material, results have been disappointing for practical thermal systems and applicat

159 Long-term results of pericardiectomy are disappointing for some patient groups, especially those

160 initial clinical trials in humans have been disappointing, highlighting a need to optimize their imm

161 Despite a long disappointing history of human trials with neurotrophins

162 this burgeoning literature has thus far been disappointing, however, leaving open the question of whi

163 Effectiveness is then often disappointing in 'real life' conditions.

164 t in the context of atherosclerosis has been disappointing in clinical studies.

165 idual neurotrophic factors (NTF) have proved disappointing in clinical trials for neuronal repair and

166 gh increasing landscape complexity can prove disappointing in fields with low soil services or in int

167 l in a subset of patients with PPH, has been disappointing in HIV-associated pulmonary hypertension a

168 xpensive and their immunogenicity has proven disappointing in human clinical trials, we have been exp

169 investigation of systemic sclerosis remains disappointing in identifying susceptibility alleles.

170 disease and even promising agents have been disappointing in large-scale clinical trials.

171 Calcium antagonists have proved disappointing in long-term congestive heart failure (CHF

172 n animal models of ALS, but have been proven disappointing in part because effective targets have not

173 However, clinical trials have been disappointing in part to dose-limiting hypercalcemia.

174 onic laryngitis, cough, and asthma have been disappointing in showing benefit of acid suppressive the

175 other hand, offer safety but have often been disappointing in terms of efficiency of nuclear delivery

176 rength composite material, it exhibits quite disappointing in terms of modulus or strength.

177 chemical compounds-for other purposes-proved disappointing in tests against Ebola virus (EBOV) infect

178 me-wide association studies (GWAS) have been disappointing in the inability of investigators to use t

179 mphoteric vectorization efforts proved to be disappointing in this series, aminoglycosidic and polyca

180 Stimulation treatments have been disappointing in vegetative state but occasionally impro

181 ognosis, particularly in advanced stages, is disappointing largely due to the resistance to conventio

182 ation for hepatocellular carcinoma have been disappointing, largely because of the high recurrence ra

183 the clinical efficacy of gene therapies were disappointing, largely because the available gene-transf

184 nts however, overall 5-year survival remains disappointing: less than 25% of patients live for 5 year

185 ) fusion F glycoprotein previously exhibited disappointing levels of RSV F immunogenicity and genetic

186 L tyrosine kinase inhibitors (TKIs) has been disappointing, often resulting in short remissions typif

187 This past year has proved to be a relatively disappointing one for the development of agents that cou

188 mor necrosis factor-alpha activity have been disappointing, or of unproven benefit at best.

189 temperature (24 degrees C) have thus far had disappointing outcome results.

190 ssays, but with a precision of only 0.92%, a disappointing outcome that led to an examination of the

191 organic solar cells, although with a rather disappointing outcome to date in terms of efficiencies.

192 This disappointing outcome was traced to unfavorable pharmaco

193 lection using drug resistance genes have had disappointing outcomes and/or require highly genotoxic m

194 Such disappointing outcomes clearly call for broadening the s

195 Disappointing outcomes in clinical trials aimed at augme

196 Disappointing outcomes of nano-sized formulations (nanof

197 which immune rejection contributes to these disappointing outcomes using an immunodeficient IL2 rece

198 istent atrial fibrillation (PersAF) have had disappointing outcomes, despite concerted clinical and r

199 systemic therapies, including taxanes, yield disappointing outcomes.

200 with the RXR ligand (rexinoid) have yielded disappointing outcomes.

201 er failure of those first-line therapies are disappointing overall, with many patients eventually req

202 d targeted therapy trials have thus far been disappointing owing to a lack of robust stratification m

203 ion methods of nanowire-like devices produce disappointing performance because of process-induced mat

204 vention of sudden arrhythmic death have been disappointing, perhaps because suppressive therapy with

205 wever, human trials with vitamin E have been disappointing, perhaps related to ineffective levels of

206 clinical studies of AR inhibitors have been disappointing, possibly due to poor potency in man.

207 age of the term "DNA vaccines," however, the disappointing potency of the DNA vaccines in humans unde

208 outcomes of somatic cell transplants remain disappointing, presumably due to lack of appropriate sup

209 A major reason for disappointing progress of psychiatric diagnostics and no

210 th attendant inflated development costs) and disappointing progress.

211 ever, progression-free survival rates remain disappointing, ranging from 40% to 50%.

212 The disappointing recent failure of fluoroquinolone-containi

213 iagnostic tools, and to understand the often disappointing response to upper airway surgery in these

214 against specific tumors have so far produced disappointing results against ovarian cancer.

215 lipoprotein (LDL) in vitro and has displayed disappointing results against the onset and development

216 Despite this, programs have yielded disappointing results and can have unintended consequenc

217 therapy with rapamycin analogues has yielded disappointing results due in part to compensatory up-reg

218 ly responsive to chemotherapy, combined with disappointing results from a recent SCLC clinical trial

219 After disappointing results from all efficacy trials conducted

220 Disappointing results from most late-stage clinical tria

221 diovascular disease paved the way to largely disappointing results from several large prevention tria

222 der in which conventional treatment leads to disappointing results in a proportion of patients.

223 DA-approved drug that has previously yielded disappointing results in clinical trials in patients wit

224 cause current pan-HDAC inhibitors have shown disappointing results in clinical trials of solid tumors

225 nation of why anti-EGFR therapies have shown disappointing results in clinical trials.

226 The disappointing results in humans should be taken as an op

227 with promising results in certain areas and disappointing results in others.

228 ion of the mismatch are also responsible for disappointing results in the application of perfusion-we

229 ation in immunologically fit individuals and disappointing results in the elderly and immunocompromis

230 t year, several promising approaches yielded disappointing results in the phase III setting (GVAX); n

231 t year, several promising approaches yielded disappointing results in the phase III setting (GVAX, sa

232 In contrast, oral agents have yielded disappointing results in the secondary prevention of acu

233 n infectious disease models but have yielded disappointing results in tumor models when tumor-associa

234 al limb ischemia all have contributed to the disappointing results of balloon angioplasty for complex

235 Despite the disappointing results of Explorer and Lunar trials, othe

236 This could explain the disappointing results of FGF-2 therapy in clinical trial

237 Angst over disappointing results of neuroprotection trials in Parki

238 trials, was then tempered by the subsequent disappointing results of randomized clinical trials.

239 e involving more diverse regimens, following disappointing results of retinoid monotherapy.

240 On the flip side, the disappointing results of rituximab in lupus nephritis pr

241 The disappointing results of the National Emphysema Treatmen

242 eart disease and may help explain the mostly disappointing results of this approach to date.

243 These disappointing results represent a policy failure within

244 These disappointing results stand in sharp contrast to estimat

245 ve been used in a small clinical trial, with disappointing results to date.

246 Disappointing results were announced for a number of lar

247 The disappointing results were attributed largely to poor ad

248 By contrast, disappointing results with antigen-based therapeutics hi

249 Unfortunately, there have been disappointing results with regard to improvement of tumo

250 Chemotherapy and radiation afford disappointing results, however, and novel therapies are

251 In light of these disappointing results, investigators have pursued altern

252 trials of glutamatergic modulators have had disappointing results, our growing understanding suggest

253 Despite disappointing results, two recent medication trials show

254 el mechanism-based treatments brought rather disappointing results, with low, if any, drug efficacy a

255 followed but were initially met with largely disappointing results.

256 dates, human trials have exclusively yielded disappointing results.

257 eradicate this viral reservoir have yielded disappointing results.

258 the myocardium using stem cells have yielded disappointing results.

259 mpts to improve adherence have often yielded disappointing results.

260 However, the clinical trials yielded disappointing results.

261 s of the inflammatory response, have yielded disappointing results.

262 y has been explored in myeloma patients with disappointing results.

263 ic strategies have so far yielded relatively disappointing results.

264 erapy for iliofemoral venous thrombosis with disappointing results.

265 w exceptions, empirical studies have yielded disappointing results.

266 ls with anticytokine therapies have produced disappointing results.

267 mmatory response, however, have thus far had disappointing results.

268 e candidates have been tried in humans, with disappointing results.

269 ion against virion proteins but have yielded disappointing results.

270 ter bodies but several times with unexpected disappointing results.

271 test this possibility, however, have yielded disappointing results.

272 performed for hemangiosarcoma (HAS) despite disappointing results.

273 c therapy for ischemic heart disease has had disappointing results.

274 ase (PD) have produced variable, but overall disappointing, results.

275 ted at tumor necrosis factor alpha have been disappointing so far, although preliminary studies with

276 ut their effect on clinical outcome has been disappointing so far, except for saphenous vein bypass g

277 ical trials for acute pancreatitis have been disappointing, so strategies that target and alter the b

278 While this disappointing state of affairs may suggest that plasma p

279 ease-modifying approaches have been thus far disappointing, steady advances are being made in the sym

280 in vitro, recent clinical trial results are disappointing, suggesting that MSC viability and/or func

281 Disappointing survival rates from out-of-hospital cardia

282 HCT service use increased over time, it was disappointing that the proportions ever testing and ever

283 es using single targeted therapies have been disappointing, therefore providing the impetus for novel

284 The results for other rTMS paradigms are disappointing thus far.

285 hase 1 and 2 clinical trials have been quite disappointing to date, and toxicities sometimes have bee

286 lts of treatment with chemotherapy have been disappointing to date, with no trials demonstrating a be

287 hibitors targeting individual RTKs have been disappointing to date.

288 cardioprotective signaling has been largely disappointing to date.

289 usable system lasts for years." It is indeed disappointing to discover that your data resources are n

290 xplain variation in population risk had been disappointing until the advent of technologies that assa

291 r prognostic accuracy of markers often prove disappointing when "discrimination" found between cancer

292 rials of antiangiogenic strategies have been disappointing when administered as single agents, such a

293 ise in some malignancies have generally been disappointing when applied to high-grade brain tumors su

294 ocyte transplantation for cirrhosis has been disappointing when compared with laboratory experience.

295 harmaceuticals targeting this class has been disappointing, where it has been a major problem to obta

296 les for diagnostic purposes have been rather disappointing with respect to their clinical validity, i

297 e resection, 5-year survival rates have been disappointing, with about 50% of patients eventually suf

298 ndritic cell (DC)-based immunotherapy remain disappointing, with DCs often displaying a tenuous capac

299 n IIb/IIIa inhibition have been consistently disappointing, with evolving evidence of increased morta

300 ed aimed at the PPTg, but outcomes have been disappointing, with little evidence that gait and postur